Loading
A phase 3 trial of Envafolimab, Gemcitabine and Oxaliplatin in biliary tract cancer, run by 3D Medicines (Sichuan) Co., Ltd., active and no longer recruiting.
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC is a phase 3 interventional study registered as NCT03478488 by 3D Medicines (Sichuan) Co., Ltd., with 480 participants enrolled, started 2018-04-16 and due to reach its primary completion in 2024-09-10. Interventions recorded: KN035 plus Gemcitabine & oxaliplatin and Gemcitabine & oxaliplatin.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Platinum agents, Monoclonal antibodies, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Oxaliplatin, Gemcitabine, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares BTC, Gemcitabine and the tag pipeline.